AS1411 aptamer improves therapeutic efficacy of PEGylated nanoliposomes loaded with gefitinib in the mice bearing CT26 colon carcinoma
Source abstract
Abstract
In this work, a tumor-targeting liposome containing anti-nucleolin aptamer AS1411 (Apt-Lip-GEF) was developed to deliver gefitinib (GEF) for the treatment of colon cancer. The prepared liposomes were characterized using their morphological properties, size dispersity, zeta potential, encapsulation efficiency, and release properties. The anti-tumor effects of Lip-GEF and Apt-Lip-GEF were measured using cytotoxicity and apoptosis-induced and quantitative real-time PCR. Furthermore, in vivo experiments were evaluated in BALB/c mice bearing CT26 colon carcinoma. Binding of AS1411 to the surface of liposomes was confirmed by gel electrophoresis. The encapsulation efficiency of the Lip-GEF and Apt-Lip-GEF obtained 91 ± 7.1% and 86 ± 5.4%, respectively, and the in vitro release of GEF from both formulations was at acceptable range. Fluorescence microscopy and flow cytometry confirmed the enhanced cellular uptake of AS1411-targeted liposomes in the CT26 cells. Cytotoxicity assay indicated that Apt-Lip-GEF had higher anti-proliferative activity than CT26 cells as positive nucleolin compared to HEK293 as negative nucleolin. At equal concentrations (98 µM), Apt-Lip-GEF was more successful than Lip-GEF in causing apoptosis and cell necrosis. The upregulation of BAX and the downregulation of PIK and AKT as well as BCL2 were observed after treatment with Apt-Lip-GEF in CT26 cells, using qRT-PCR analysis. In cancer model mice, treatment with Apt-Lip-GEF compared with free GEF showed a significant reduction in tumor growth; moreover, the lowest rates of weight change were observed in Apt-Lip-GEF group. Modified nanoliposome acts as a successful delivery system for gefitinib and has high potential for the treatment of colorectal cancer. Graphical Abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Siegel RL, Miller KD, Fuchs HE et al (2021) Cancer statistics, 2021. CA: Cancer J Clin 71(1):7–33
2. Hatami A, Heydarinasab A, Akbarzadehkhiyavi A et al (2021) An introduction to nanotechnology and drug delivery. Chem Methodologies 5(2):153–165
3. Molaei P, Mahaki H, Manoochehri H, et al (2022) Binding sites of anticancer drugs on human serum albumin (HSA): a review. Protein Pept Lett10.2174/0929866529666220426124834 ↗
4. Manoochehri H, Asadi S, Tanzadehpanah H et al (2021) CDC25A is strongly associated with colorectal cancer stem cells and poor clinical outcome of patients. Gene Reports 25:10141510.1016/j.genrep.2021.101415 ↗
5. Tanzadehpanah H, Mahaki H, Moghadam NH et al (2019) Binding site identification of anticancer drug gefitinib to HSA and DNA in the presence of five different probes. J Biomol Struct Dyn 37(4):823–83610.1080/07391102.2018.1441073 ↗
6. Moghadam NH, Salehzadeh S, Rakhtshah J et al (2018) Improving antiproliferative effect of the nevirapine on Hela cells by loading onto chitosan coated magnetic nanoparticles as a fully biocompatible nano drug carrier. Int J Biol Macromol 118:1220–122810.1016/j.ijbiomac.2018.06.144 ↗
7. Tanzadehpanah H, Mahaki H, Moradi M et al (2018) Human serum albumin binding and synergistic effects of gefitinib in combination with regorafenib on colorectal cancer cell lines. Color Cancer 7(2):CRC0310.2217/crc-2017-0018 ↗
8. Bahmani A, Tanzadehpanah H, Hosseinpour Moghadam N et al (2021) Introducing a pyrazolopyrimidine as a multi-tyrosine kinase inhibitor, using multi-QSAR and docking methods. Mol Diversity 25(2):949–96510.1007/s11030-020-10080-8 ↗
9. Rawluk J, Waller CF (2018) Gefitinib. Small molecules in oncology. 235–24610.1007/978-3-319-91442-8_16 ↗
10. Thierry B (2009) Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr Drug Deliv 6(4):391–40310.2174/156720109789000474 ↗
11. Mozafari M (2010) Nanoliposomes: preparation and analysis. Springer, Liposomes, pp 29–5010.1007/978-1-60327-360-2_2 ↗
12. Huang D, Sun L, Huang L et al (2021) Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. Journal of Personalized Medicine 11(2):12410.3390/jpm11020124 ↗
13. Han J, Gao L, Wang J et al (2020) Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy. J Cancer 11(23):690210.7150/jca.49532 ↗
14. Pei X, Zhang J, Liu J (2014) Clinical applications of nucleic acid aptamers in cancer. Mol Clin Oncol 2(3):341–34810.3892/mco.2014.255 ↗
15. Xiang D, Shigdar S, Qiao G et al (2015) Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine. Theranostics 5(1):2310.7150/thno.10202 ↗
16. Yazdian-Robati R, Bayat P, Oroojalian F et al (2020) Therapeutic applications of AS1411 aptamer, an update review. Int J Biol Macromol 155:1420–143110.1016/j.ijbiomac.2019.11.118 ↗
17. Manoochehri H, Jalali A, Tanzadehpanah H, et al (2022) Aptamer-conjugated nanoliposomes containing COL1A1 siRNA sensitize CRC cells to conventional chemotherapeutic drugs. Colloids Surf B Biointerfaces :11271410.1016/j.colsurfb.2022.112714 ↗
18. Chen Z, Xu X (2016) Roles of nucleolin: focus on cancer and anti-cancer therapy. Saudi Med J 37(12):131210.15537/smj.2016.12.15972 ↗
19. Farahbakhsh Z, Zamani MR, Rafienia M et al (2020) In silico activity of AS1411 aptamer against nucleolin of cancer cells. Iranian J Blood Cancer 12(3):95–100
20. Bates PJ, Laber DA, Miller DM et al (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–16410.1016/j.yexmp.2009.01.004 ↗
21. Rohilla S, Awasthi R, Mehta M et al (2022) Preparation and evaluation of gefitinib containing nanoliposomal formulation for lung cancer therapy. BioNanoScience 12(1):241–25510.1007/s12668-022-00938-6 ↗
22. Hu Y, Zhang J, Hu H et al (2020) Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer. Cell Cycle 19(24):3581–359410.1080/15384101.2020.1852756 ↗
23. Tanzadehpanah H, Bahmani A, Hosseinpour Moghadam N et al (2021) Synthesis, anticancer activity, and β-lactoglobulin binding interactions of multitargeted kinase inhibitor sorafenib tosylate (SORt) using spectroscopic and molecular modelling approaches. Luminescence 36(1):117–12810.1002/bio.3929 ↗
24. Zhou X, Yung B, Huang Y et al (2012) Novel liposomal gefitinib (L-GEF) formulations. Anticancer Res 32(7):2919–2923
25. Afshar S, Pashaki AS, Najafi R et al (2020) Cross-resistance of acquired radioresistant colorectal cancer cell line to gefitinib and regorafenib. Iranian J Med Sci 45(1):50
26. Zhang Q, Li R, Chen X et al (2017) Effect of weekly or daily dosing regimen of gefitinib in mouse models of lung cancer. Oncotarget 8(42):7244710.18632/oncotarget.19785 ↗
27. Moradi M, Najafi R, Amini R et al (2019) Remarkable apoptotic pathway of hemiscorpius lepturus scorpion venom on CT26 cell line. Cell Biol Toxicol 35(4):373–38510.1007/s10565-018-09455-3 ↗
28. Mahaki H, Jabarivasal N, Sardarian K et al (2019) The effects of extremely low-frequency electromagnetic fields on c-Maf, STAT6, and RORα expressions in spleen and thymus of rat. Electromagn Biol Med 38(2):177–18310.1080/15368378.2019.1608832 ↗
29. Duan S, Yu Y, Lai C et al (2018) Vincristine-loaded and sgc8-modified liposome as a potential targeted drug delivery system for treating acute lymphoblastic leukemia. J Biomed Nanotechnol 14(5):910–92110.1166/jbn.2018.2530 ↗
30. Li L, Hou J, Liu X et al (2014) Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 35(12):3840–385010.1016/j.biomaterials.2014.01.019 ↗
31. Liao Z-X, Chuang E-Y, Lin C-C et al (2015) An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance. J Control Release 208:42–5110.1016/j.jconrel.2015.01.032 ↗
32. Moosavian SA, Abnous K, Akhtari J et al (2018) 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Artif Cells, Nanomed Biotechnol 46(8):2054–2065
33. Hernández-Esquivel R-A, Navarro-Tovar G, Zárate-Hernández E, et al (2021) Solid lipid nanoparticles (SLN). Nanocomposite materials for biomedical and energy storage applications: IntechOpen10.5772/intechopen.102536 ↗
34. Abdullah JAA, Jiménez-Rosado M, Perez-Puyana V et al (2022) Green synthesis of FexOy nanoparticles with potential antioxidant properties. Nanomaterials 12(14):244910.3390/nano12142449 ↗
35. Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63(3):131–13510.1016/j.addr.2010.03.011 ↗
36. Abdullah JAA, Jiménez-Rosado M, Benítez JJ et al (2022) Biopolymer-based films reinforced with FexOy-nanoparticles Polymers 14(21):4487
37. Satapathy S, Patro CS (2022) Solid lipid nanoparticles for efficient oral delivery of tyrosine kinase inhibitors: a nano targeted cancer drug delivery [review]. Adv Pharm Bull 12(2):298–308
38. Pourhassan H, Clergeaud G, Hansen AE et al (2017) Revisiting the use of sPLA2-sensitive liposomes in cancer therapy. J Control Release 261:163–17310.1016/j.jconrel.2017.06.024 ↗
39. Needham D, Anyarambhatla G, Kong G et al (2000) A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Can Res 60(5):1197–1201
40. Boratto F, Franco M, Barros A et al (2020) Alpha-tocopheryl succinate improves encapsulation, pH-sensitivity, antitumor activity and reduces toxicity of doxorubicin-loaded liposomes. Eur J Pharm Sci 144:10520510.1016/j.ejps.2019.105205 ↗
41. Silva JO, Fernandes RS, Lopes SC et al (2016) pH-sensitive, long-circulating liposomes as an alternative tool to deliver doxorubicin into tumors: a feasibility animal study. Mol Imag Biol 18(6):898–90410.1007/s11307-016-0964-7 ↗
42. Laginha KM, Verwoert S, Charrois GJ et al (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11(19):6944–694910.1158/1078-0432.CCR-05-0343 ↗
43. Abdullah Jaa, Jiménez-Rosado M, Guerrero A, et al. Eco-friendly synthesis of ZnO-nanoparticles using Phoenix dactylifera L. polyphenols: physicochemical, microstructural and functional assessment. 2022.10.21203/rs.3.rs-1934475/v1 ↗
44. Riahi MM, Sahebkar A, Sadri K et al (2018) Stable and sustained release liposomal formulations of celecoxib: in vitro and in vivo anti-tumor evaluation. Int J Pharm 540(1–2):89–9710.1016/j.ijpharm.2018.01.039 ↗
45. Su Y, Liu M, Xiong Y et al (2019) Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon. Drug Deliv Transl Res 9(1):66–7510.1007/s13346-018-0588-3 ↗
46. Liu J, Ma H, Wei T et al (2012) CO 2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chem Commun 48(40):4869–487110.1039/c2cc31697h ↗
47. Zahmatkeshan M, Gheybi F, Rezayat SM et al (2016) Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Eur J Pharm Sci 86:125–13510.1016/j.ejps.2016.03.009 ↗
48. Yu Z, Li X, Duan J et al (2020) Targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel. Int J Nanomed 15:673710.2147/IJN.S267177 ↗
49. Yao F, An Y, Li X et al (2020) Targeted therapy of colon cancer by aptamer-guided holliday junctions loaded with doxorubicin. Int J Nanomed 15:211910.2147/IJN.S240083 ↗
50. Sheykhhasan M, Ahmadyousefi Y, Seyedebrahimi R, et al (2021) DLX6-AS1: a putative lncRNA candidate in multiple human cancers. Expert Rev Mol Med 2310.1017/erm.2021.17 ↗
51. Mahaki H, Jabarivasal N, Sardarian K et al (2020) Effects of various densities of 50 Hz electromagnetic field on serum IL-9, IL-10, and TNF-α levels. Int J Occup Environ Med 11(1):2410.15171/ijoem.2020.1572 ↗
52. Lebedeva IV, Su Z-Z, Sarkar D, et al (Eds) (2003) Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Seminars in cancer biology: Elsevier10.1016/S1044-579X(02)00134-7 ↗
53. Manoochehri H, Jalali A, Tanzadehpanah H, et al (2021) Identification of key gene targets for sensitizing colorectal cancer to chemoradiation: an integrative network analysis on multiple transcriptomics data. J Gastrointest Cancer :1–2010.1007/s12029-021-00690-2 ↗
54. Dlamini Z, Mbita Z, Zungu M (2004) Genealogy, expression, and molecular mechanisms in apoptosis. Pharmacol Ther 101(1):1–1510.1016/j.pharmthera.2003.08.005 ↗
55. Zheng L, Gong W, Liang P et al (2014) Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer. Tumor Biol 35(5):4095–409910.1007/s13277-013-1535-z ↗
56. Osman G, Rodriguez J, Chan SY et al (2018) PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J Control Release 285:35–4510.1016/j.jconrel.2018.07.001 ↗
57. Vonarbourg A, Passirani C, Saulnier P et al (2006) Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27(24):4356–437310.1016/j.biomaterials.2006.03.039 ↗